BONEX logo

Bonesupport Holding AB (publ) Stock Price

OM:BONEX Community·SEK 19.9b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 29 Fair Values set on narratives written by author

BONEX Share Price Performance

SEK 301.60
-8.60 (-2.77%)
28.1% undervalued intrinsic discount
SEK 419.75
Fair Value
SEK 301.60
-8.60 (-2.77%)
28.4% undervalued intrinsic discount
SEK 421.20
Fair Value
Price SEK 301.60
AnalystConsensusTarget SEK 421.20

BONEX Community Narratives

AnalystConsensusTarget·Updated
Fair Value SEK 419.75 28.1% undervalued intrinsic discount

FDA Submission And US Launch Will Drive Success

0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative

Recent BONEX News & Updates

Bonesupport Holding AB (publ)'s (STO:BONEX) Shares May Have Run Too Fast Too Soon

Aug 25
Bonesupport Holding AB (publ)'s (STO:BONEX) Shares May Have Run Too Fast Too Soon

Bonesupport Holding's (STO:BONEX) Soft Earnings Are Actually Better Than They Appear

Jul 23
Bonesupport Holding's (STO:BONEX) Soft Earnings Are Actually Better Than They Appear

Bonesupport Holding AB (publ)'s (STO:BONEX) Intrinsic Value Is Potentially 80% Above Its Share Price

Jun 28
Bonesupport Holding AB (publ)'s (STO:BONEX) Intrinsic Value Is Potentially 80% Above Its Share Price

Analyst Estimates: Here's What Brokers Think Of Bonesupport Holding AB (publ) (STO:BONEX) After Its First-Quarter Report

Apr 28
Analyst Estimates: Here's What Brokers Think Of Bonesupport Holding AB (publ) (STO:BONEX) After Its First-Quarter Report

Bonesupport Holding AB (publ) Key Details

SEK 1.1b

Revenue

SEK 78.7m

Cost of Revenue

SEK 983.8m

Gross Profit

SEK 835.8m

Other Expenses

SEK 148.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 23, 2025
Earnings per share (EPS)
2.25
Gross Margin
92.59%
Net Profit Margin
13.93%
Debt/Equity Ratio
0%

Bonesupport Holding AB (publ) Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Exceptional growth potential with flawless balance sheet.

2 Risks
3 Rewards

About BONEX

Founded
1999
Employees
140
CEO
Torbjorn Skold
WebsiteView website
www.bonesupport.com

Bonesupport Holding AB (publ), an orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management. In addition, the company develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. Bonesupport Holding AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Swedish Market Performance

  • 7 Days: 2.5%
  • 3 Months: 3.2%
  • 1 Year: -1.0%
  • Year to Date: 3.1%
Over the last 7 days, the market has risen 2.5%, driven by gains of 3.5% in the Industrials sector. The market has been flat overall in the last year. Earnings are forecast to grow by 16% annually. Market details ›